Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

pharmiweb.com today archive

3259 PWToday Stories

Velabs Therapeutics to Cooperate with BioMed X in the Field of Immunology

07 Jan 19

Velabs Therapeutics, specializing in the fast generation of functional therapeutic antibodies, today announced that it has entered into a collaboration agreement with BioMed X Innovation Center, Heidelberg. The collaboration will capitalize on Velabs’ microfluidics-based technology in the field of T-cell screening.

The BioMed X Innovation Center is a new collaboration model at the interface between academia and industry. BioMed X is using the Velabs platform to support the research team of John Lindner to explore new concepts for rapid identification of auto-antigens in autoimmune diseases. The research team, sponsored by Janssen Research & Development, LLC, will use high-throughput microfluidic screening approaches to couple T-cell receptor specificity with auto-antigens.

Velabs Therapeutics, a recent startup company of the European Molecular Biology Laboratory (EMBL), is a pioneer in microfluidic technology for functional screening of antibodies and single immune cells. The high-throughput screening platform allows for testing millions of correctly paired fully natural IgGs from humans and mice for therapeutic effects, rather than just for binding. Results are obtained in only a fraction of the time required by other technologies. The company offers customized screening services for users worldwide. Besides carrying out service projects, Velabs is currently also establishing its own proprietary pipeline of therapeutic antibody candidates for further joint development with pharma partners.

 “We are excited by this new cooperation with one of BioMed X’s top research teams”, says Christoph Antz, Managing Director of Velabs. “The company’s capacities in fast screening of single cells and functional antibodies will strongly support a superior performance of BioMed X’s research team.”, adds Christoph Merten, scientific founder and CSO of Velabs.

“In order to address the central challenge of screening and characterizing different immune cells at large scale, the research team chose Velabs’ technology as the most suitable and promising microfluidic screening platform available”, says Christian Tidona, founder and Managing Director of BioMed X.

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.